The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
CCL
Vol.
36
No.
2
February 22, 2013
- Abraxane Combination Improves Survival In Treatment-Naïve Metastatic Disease
- Avastin Increases Overall Survival 3.7 Months
- First-Line Bendamustine Doubles PFS In Non-Hodgkin and Mantle Cell Lymphoma
- Phase III Trial of ThermoDox Fails to Meet Primary Endpoint
- Neulasta Reduces Incidence Of Febrile Neutropenia
- Tivozanib Does Not Improve OS Compared to Sorafenib
- In Surgery vs Radiotherapy, Outcome Differences Equalize After 15 Years Follow-up
- Genomic Test More Accurate In Predicting Metastasis Than PSA, Tumor Stage & Grade
- Protein May Link Obesity To Cancer Aggressiveness
- “Triple-Negative” Should Be Split Into Subtypes, Say Researchers
- NCI CTEP Approved Trials For the Month of February
- Avastin Combination Approved For Metastatic Colorectal Cancer
- FDA Grants Priority Review To Two Drugs in NSCLC
TCL
Vol.
39
No.
10
March 08, 2013
- NIH Director Collins Challenged On Capitol Hill Over NCI-Funded Research Linking Tea Party With Tobacco Companies
- Federal Budget Cuts Implemented March 1; HHS Agencies Grapple with Consequences
- In Brief: Breakthrough Prize Awarded to 11 Scientists
- Harold Varmus Addresses the NCI Board of Scientific Advisors
TCL
Vol.
39
No.
12
March 22, 2013
TCL
Vol.
39
No.
13
March 29, 2013
- MD Anderson Faculty Slam Leadership, Question Moon Shots, Bemoan Workload
- In Their Own Words: A 64-page Internal Report with over 1,500 Faculty Comments on MD Anderson Morale
- MD Anderson President Ronald DePinho: “Some of the Feedback was Humbling”
- Reviews of the Faculty Report by Irwin Krakoff, Robert Cook-Deegan, and Michael Katz
- 60 Minutes Report “Deception at Duke” Wins Peabody Award
CCL
Vol.
36
No.
3
March 29, 2013
- Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint
- Study: Rencarex Treatment Efficacy Increases With CAIX Antigen Density in Tumor Tissue
- DSMB Recommends Discontinuing Phase III Perifosine Combination Trial
- 51% Control Rate Achieved In Phase II Trial of Elderly Patients
- Study: Partial Kidney Removal Leads to Greater Survival
- Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint
- AIDS Cachexia Drug Stabilizes Body Weight, Muscle Mass
- Two Children Achieve Remission With CD19 Immunotherapy
- Adjuvant Chemotherapy Unneeded In Children with Low-Risk Disease
- Study: Oncotype DX Score Can Predict Local Recurrence
- BRAF Mutation Testing Classifies Indeterminate FNA Samples
- NCI CTEP Approved Trials For the Month of March
- FDA Approves Lymphoseek For Imaging Lymph Nodes
